ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, has raised US$22.4m in its Series B financing. New investment was received from…
Australia: ENA Respiratory attracts US$22.4m to fund Phase II development of INNA-051 nasal spray
…
…






